References
- TangHCChenYCInsight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanomaInt J Nanomedicine2015103131314625960652
- PenmanCLFaulknerCLowisSPKurianKMCurrent understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomasFront Oncol201555425785246
- WhelerJYelenskyRFalchookGNext generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceBMC Cancer2015156125886620
- PettirossiVSantiAImperiEBRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activityBlood20151251207121625480661
- TiacciESchiavoniGMartelliMPConstant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemiaHaematologica20139863563923349307
References
- HartsoughEShaoYAplinAEResistance to RAF inhibitors revisitedJ Invest Dermatol2014134231932524108405
- TangHCChenYCMolecular insight and resolution for tumors harboring the H-ras (G12V) mutationRSC Adv20155272062320633
- TangHCChenCYDrug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicineBiomed Res Int2014201479874225045703